» Articles » PMID: 10984565

Polymorphisms in the Factor VII Gene and the Risk of Myocardial Infarction in Patients with Coronary Artery Disease

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2000 Sep 14
PMID 10984565
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Background: High plasma levels of coagulation factor VII have been suggested to be predictors of death due to coronary artery disease. Since polymorphisms in the factor VII gene contribute to variations in factor VII levels, such polymorphisms may be associated with the risk of myocardial infarction, which is precipitated by thrombosis.

Methods: We studied a total of 444 patients, 311 of whom had severe, angiographically documented coronary atherosclerosis. Of these 311 patients, 175 had documentation of a previous myocardial infarction. As a control group, 133 patients with normal coronary arteriograms were also included. We measured the levels of activated factor VII and assessed three polymorphisms in the factor VII gene, one involving the promoter (A1 and A2 alleles), one involving the catalytic region (R353Q), and one involving intron 7.

Results: Each of the polymorphisms influenced factor VII levels. Patients with the A2A2 and QQ genotypes had the lowest levels of activated factor VII (66 percent and 72 percent lower, respectively, than the levels in patients with the wild-type genotypes). The frequencies of the various genotypes in the patients free of coronary artery disease were similar to those in the entire population of patients with coronary artery disease. In the latter group, there were significantly more heterozygotes and homozygotes for the A2 and Q alleles among those who had not had a myocardial infarction than among those who had had an infarction (P=0.008 for the presence of the promoter polymorphism and P=0.01 for the presence of the R353Q polymorphism by chi-square analysis). The adjusted odds ratio for myocardial infarction among the patients with the A1A2 or RQ genotype was 0.47 (95 percent confidence interval, 0.27 to 0.81).

Conclusions: Our findings suggest that certain factor VII genotypes have a role in protection against myocardial infarction. This may explain why some patients do not have myocardial infarction despite the presence of severe coronary atherosclerosis.

Citing Articles

Frequency and Association of Polymorphisms in F2, F7, and PROS1 Coagulation Genes with Disease Severity in Coronavirus Disease 2019.

Alshaya D, Alzamil L, Alghamdi A, Alshammari L, Alhowaiti S, Bohol M Clin Appl Thromb Hemost. 2024; 30:10760296241295731.

PMID: 39497411 PMC: 11536613. DOI: 10.1177/10760296241295731.


miRNAs Epigenetic Tuning of Wall Remodeling in the Early Phase after Myocardial Infarction: A Novel Epidrug Approach.

Salvatori F, DAversa E, Serino M, Singh A, Secchiero P, Zauli G Int J Mol Sci. 2023; 24(17).

PMID: 37686073 PMC: 10487654. DOI: 10.3390/ijms241713268.


Current Practice of Percutaneous Coronary Intervention in Patients With Coagulation Disorders.

El Khoury M, Karam B, Tabet R, Lafferty J, Snyder S Cureus. 2021; 13(9):e18284.

PMID: 34722061 PMC: 8545607. DOI: 10.7759/cureus.18284.


Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis.

Bernardi F, Mariani G Haematologica. 2021; 106(2):351-362.

PMID: 33406812 PMC: 7849579. DOI: 10.3324/haematol.2020.248542.


Essential thrombocythemia: a hemostatic view of thrombogenic risk factors and prognosis.

Maleknia M, Shahrabi S, Ghanavat M, Vosoughi T, Saki N Mol Biol Rep. 2020; 47(6):4767-4778.

PMID: 32472297 DOI: 10.1007/s11033-020-05536-x.